Frailty Does Not Hinder Dapagliflozin's HFrEF Impact: DAPA-H

In fact, the greatest benefits were seen in the most-frail patients—not just for outcomes but also for quality of life.

Related Keywords

Denmark , United Kingdom , Scotland , Alexandert Sandhu , Boehringer Ingelheim Eli Lilly , Astrazeneca , Md University Of Glasgow , Copenhagen University Hospital Rigshospitalet , Md Stanford University School Of Medicine , Drug Administration , Eli Lilly , Internal Medicine , Stanford University School , Kansas City Cardiomyopathy Questionnaire , With Dapagliflozin ,